CRB-913
Phase 1Small molecule
CRB-913 is one of 44 small molecule programs targeting Obesity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Elecoglipron
AstraZenecaPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CRB-913. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCorbus Pharmaceuticals Inc.